Johnson & Johnson is a U.S.-based multinational healthcare company headquartered in New Brunswick, New Jersey. It operates through two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company discovers, develops, manufactures, and markets prescription therapeutics and medical technologies worldwide, with focus areas that include oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. Janssen Biotech, Inc., and related Janssen entities form part of its pharmaceutical operations.
From a chemicals and manufacturing perspective, Johnson & Johnson’s pharmaceutical business spans small-molecule active pharmaceutical ingredient (API) synthesis, biologics and monoclonal antibody production, and sterile, parenteral, and solid-dose drug product manufacturing. These activities are supported by a global R&D and GMP manufacturing network, alongside extensive external partnerships and licensing arrangements. The company maintains large-scale quality, regulatory, and supply chain capabilities to supply medicines to markets worldwide.
Also known as Janssen Biotech, Inc..
chemXplore tracks 1 project involving J&J, of which one is active.
J&J's role on them: Owner.
1 expansion.
Single CARVYKTI infusion produced treatment-free, progression-free remissions at five years in half of early-line relapsed/refractory multiple myeloma patients.
Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.
Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.
Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.
FDA cleared therapy for wAIHA in patients ≥12 previously or currently treated with corticosteroids; showed rapid hemoglobin gains and durable responses in Phase 2/3 ENERGY.
OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.
Adds Firelink™ degrader antibody conjugate platform to target pan‑KRAS and other hard‑to‑treat solid tumors; transaction carries near‑term R&D charge and EPS dilution.
By country, the most active first. active / all projects
